{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017919","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.878405+00:00","generated_at":"2026-06-15T22:16:30.044136+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Crinetics Q1 net loss $46M; paltusotine Phase 3 PATHFNDR-1 data on track for Q3 2023","bullets":["Net loss $46.0M for Q1 2023 vs $34.6M in Q1 2022; R&D expenses $38.5M, G&A $12.2M.","Paltusotine PATHFNDR-1 (acromegaly) enrollment complete; topline data expected Q3 2023.","PATHFNDR-2 enrollment target increased to up to 98; topline data expected Q1 2024.","Phase 2 open-label study of paltusotine in carcinoid syndrome; preliminary data expected Q4 2023.","CRN04777 Phase 2 study for congenital hyperinsulinism on clinical hold; additional info to be submitted to FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017919","json":"https://secwatch.observer/filing/0000950170-23-017919.json","markdown":"https://secwatch.observer/filing/0000950170-23-017919.md","text":"https://secwatch.observer/filing/0000950170-23-017919.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023017919/0000950170-23-017919-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023017919/crnx-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:16:30.044136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"faec573783393951b495477d14f61e1c9614c3a1","claim":"Crinetics Pharmaceuticals, Inc. reported the first quarter ended March 31, 2023 results: revenue $2.7 million, net income Net loss of $46.0 million.","evidence_excerpt":"for the three months ended March 31, 2023, compared to $8.7 million for the same period in 2022. The increase was primarily attributable to an increase in personnel costs of $2.7 million and an increase in other corporate expenditures of $0.8 million. • Net loss for the three months ended March 31, 2023 was $46.0 million, compared to a net loss of $34.6 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023017919/0000950170-23-017919-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$2.7 million"},{"label":"Net income","value":"Net loss of $46.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}